Triple-combo drug shows promise against antiviral-resistant H1N1, researcher says (w/ Video)

An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.

In laboratory testing, the triple combination of oseltamivir (Tamiflu), amantadine (Symmetrel) and ribavirin showed a significant capacity to stop growth, says Mark Prichard, Ph.D, who serves on the board of directors of the International Society for Antiviral Research. The combo drug works better in the test tube than currently recommended single or double antiviral therapies used to treat both seasonal and swine flu strains, he says.

Prichard presented his data in September at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy held in San Francisco. The triple-combo testing is led by Adamas Pharmaceuticals, Inc. based in Emeryville, California.

"These findings suggest strongly that the triple combo is highly synergistic against , meaning it strikes multiple targets within H1N1 flu and other strains," Prichard says. "Only human testing will determine for sure, but this combo has the potential to be the of choice for serious flu infection and to address Tamiflu resistance."

In this video, noted virologist Mark Prichard, Ph.D., discusses pandemic antiviral resistance. Credit: UAB

The synergy was seen in and seasonal flu strains, as well as H3N2 seasonal flu and the highly pathogenic H5N1 avian , Prichard says. The dosing and timing of the combo mixture is protected information by Adamas. The company is starting human testing in the Southern Hemisphere, and has plans to begin human testing in North America once approval is obtained.

Because flu infection typically lasts for shorter periods of time than many other , the three-pronged antiviral approach means the circulating strains of flu virus may not have time to develop resistance to the combo, Prichard says. "That's why this research is so timely, and why antiviral safety and testing data is crucial.

"If this triple combo could reduce the impact to families and the healthcare system that comes from serious flu cases, we would be thrilled."

Source: University of Alabama at Birmingham (news : web)

Citation: Triple-combo drug shows promise against antiviral-resistant H1N1, researcher says (w/ Video) (2009, October 27) retrieved 28 March 2024 from https://medicalxpress.com/news/2009-10-triple-combo-drug-antiviral-resistant-h1n1-video.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Flu strains developing resistance to key antiviral drug: WHO

 shares

Feedback to editors